{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:36:09Z","timestamp":1786703769811,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s15010-026-02807-w","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:26:58Z","timestamp":1778228818000},"page":"1883-1896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of praziquantel combined with artemisinin derivatives versus praziquantel monotherapy for schistosomiasis: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"54","author":[{"given":"Yao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"11","key":"2807_CR1","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1473-3099(22)00221-3","volume":"22","author":"NC Lo","year":"2022","unstructured":"Lo NC, Bezerra FSM, Colley DG, Fleming FM, Homeida M, Kabatereine N, Kabole FM, King CH, Mafe MA, Midzi N, et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect Dis. 2022;22(11):e327\u201335.","journal-title":"Lancet Infect Dis"},{"key":"2807_CR2","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.actatropica.2024.107504","volume":"261","author":"Q Li","year":"2025","unstructured":"Li Q, Li YL, Guo SY, Li SZ, Wang Q, Lin WN, Zhang LJ, Li SZ, Zhou XN, Xu J. Global trends of schistosomiasis burden from 1990 to 2021 across 204 countries and territories: Findings from GBD 2021 study. Acta Trop. 2025;261:107504.","journal-title":"Acta Trop"},{"issue":"3","key":"2807_CR3","first-page":"221","volume":"36","author":"L Zhang","year":"2024","unstructured":"Zhang L, He J, Yang F, Dang H, Li Y, Guo S, Li S, Cao C, Xu J, Li S. [Progress of schistosomiasis control in People\u2019s Republic of China in 2023]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi\u2009=\u2009Chinese. J Schistosomiasis Control. 2024;36(3):221\u20137.","journal-title":"J Schistosomiasis Control"},{"key":"2807_CR4","doi-asserted-by":"crossref","unstructured":"Aula OP, McManus DP, Jones MK, Gordon CA. Schistosomiasis with a focus on Africa. Trop Med Infect Dis. 2021;6(3):109.","DOI":"10.3390\/tropicalmed6030109"},{"key":"2807_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12688\/wellcomeopenres.15754.1","volume":"5","author":"HC Turner","year":"2020","unstructured":"Turner HC, French MD, Montresor A, King CH, Rollinson D, Toor J. Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs. Wellcome Open Res. 2020;5:45.","journal-title":"Wellcome Open Res"},{"key":"2807_CR6","doi-asserted-by":"crossref","unstructured":"Nogueira RA, Lira MGS, Lic\u00e1 ICL, Fraz\u00e3o GCCG, Dos Santos VAF, Filho ACCM, Rodrigues JGM, Miranda GS, Carvalho RC, Nascimento FRF. Praziquantel: an update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. Mol Biochem Parasitol. 2022;252:111531.","DOI":"10.1016\/j.molbiopara.2022.111531"},{"issue":"12","key":"2807_CR7","doi-asserted-by":"publisher","first-page":"e0243224","DOI":"10.1371\/journal.pone.0243224","volume":"15","author":"A Zacharia","year":"2020","unstructured":"Zacharia A, Mushi V, Makene T. A systematic review and meta-analysis on the rate of human schistosomiasis reinfection. PloS One. 2020;15(12):e0243224.","journal-title":"PloS One"},{"issue":"1","key":"2807_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40249-017-0286-2","volume":"6","author":"R Bergquist","year":"2017","unstructured":"Bergquist R, Utzinger J, Keiser J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? Infect Dis Poverty. 2017;6(1):74.","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"2807_CR9","doi-asserted-by":"publisher","first-page":"e0009189","DOI":"10.1371\/journal.pntd.0009189","volume":"15","author":"M Fukushige","year":"2021","unstructured":"Fukushige M, Chase-Topping M, Woolhouse MEJ, Mutapi F. Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): a systematic review and meta-analysis of factors influence its efficacy. PLoS Negl Trop Dis. 2021;15(3):e0009189.","journal-title":"PLoS Negl Trop Dis"},{"issue":"625","key":"2807_CR10","doi-asserted-by":"publisher","first-page":"eabj9114","DOI":"10.1126\/scitranslmed.abj9114","volume":"13","author":"W Le Clec\u2019h","year":"2021","unstructured":"Le Clec\u2019h W, Chevalier FD, Mattos ACA, Strickland A, Diaz R, McDew-White M, Rohr CM, Kinung\u2019hi S, Allan F, Webster BL, et al. Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel. Sci Transl Med. 2021;13(625):eabj9114.","journal-title":"Sci Transl Med"},{"key":"2807_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0065-308X(10)73009-8","volume":"73","author":"S-H Xiao","year":"2010","unstructured":"Xiao S-H, Keiser J, Chen M-G, Tanner M, Utzinger J. Research and development of antischistosomal drugs in the People\u2019s Republic of China a 60-year review. Adv Parasitol. 2010;73:231\u201395.","journal-title":"Adv Parasitol"},{"key":"2807_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin C-S, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"key":"2807_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1756-3305-4-201","volume":"4","author":"R Liu","year":"2011","unstructured":"Liu R, Dong H-F, Guo Y, Zhao Q-P, Jiang M-S. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasites Vectors. 2011;4:201.","journal-title":"Parasites Vectors"},{"key":"2807_CR14","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research ed.). 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"10","key":"2807_CR15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1086\/324004","volume":"184","author":"S Borrmann","year":"2001","unstructured":"Borrmann S, Szlez\u00e1k N, Faucher JF, Matsiegui PB, Neubauer R, Binder RK, Lell B, Kremsner PG. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis. 2001;184(10):1363\u20136.","journal-title":"J Infect Dis"},{"issue":"10","key":"2807_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1046\/j.1365-3156.2000.00628.x","volume":"5","author":"D De Clercq","year":"2000","unstructured":"De Clercq D, Vercruysse J, Verl\u00e9 P, Kongs A, Diop M. What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop Med Int Health. 2000;5(10):744\u20136.","journal-title":"Trop Med Int Health"},{"issue":"10","key":"2807_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2471\/BLT.08.053041","volume":"86","author":"X-Y Hou","year":"2008","unstructured":"Hou X-Y, McManus DP, Gray DJ, Balen J, Luo X-S, He Y-K, Ellis M, Williams GM, Li Y-S. A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China. Bull World Health Organ. 2008;86(10):788\u201395.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"2807_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trstmh.2008.08.002","volume":"103","author":"PC Inyang-Etoh","year":"2009","unstructured":"Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Trans Royal Soc Trop Med Hygiene. 2009;103(1):38\u201344.","journal-title":"Trans Royal Soc Trop Med Hygiene"},{"issue":"7","key":"2807_CR19","doi-asserted-by":"publisher","first-page":"e2975","DOI":"10.1371\/journal.pntd.0002975","volume":"8","author":"J Keiser","year":"2014","unstructured":"Keiser J, Silu\u00e9 KD, Adiossan LK, N\u2019Guessan NA, Monsan NC, Utzinger J, N\u2019Goran EK. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis. 2014;8(7):e2975.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"2807_CR20","doi-asserted-by":"publisher","first-page":"e0008619","DOI":"10.1371\/journal.pntd.0008619","volume":"14","author":"RH Mnkugwe","year":"2020","unstructured":"Mnkugwe RH, Minzi O, Kinung\u2019hi S, Kamuhabwa A, Aklillu E. Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: a randomized, non-inferiority clinical trial. PLoS Negl Trop Dis. 2020;14(9):e0008619.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2807_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13071-024-06359-6","volume":"17","author":"CO Obonyo","year":"2024","unstructured":"Obonyo CO, Rawago FO, Makworo NK, Muok EMO. Efficacy and safety of single-dose artesunate plus sulfalene\/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial. Parasites Vect. 2024;17(1):279.","journal-title":"Parasites Vect"},{"issue":"2","key":"2807_CR22","doi-asserted-by":"publisher","first-page":"e0073924","DOI":"10.1128\/aac.00739-24","volume":"69","author":"CO Obonyo","year":"2025","unstructured":"Obonyo CO, Were VO, Wamae P, Muok EMO. Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial. Antimicrob Agents Chemother. 2025;69(2):e0073924.","journal-title":"Antimicrob Agents Chemother"},{"key":"2807_CR23","doi-asserted-by":"publisher","first-page":"2625255","DOI":"10.1155\/2021\/2625255","volume":"2021","author":"T Hailegebriel","year":"2021","unstructured":"Hailegebriel T, Nibret E, Munshea A. Efficacy of praziquantel for the treatment of human Schistosomiasis in Ethiopia: a systematic review and meta-analysis. J Trop Med. 2021;2021:2625255.","journal-title":"J Trop Med"},{"key":"2807_CR24","doi-asserted-by":"publisher","first-page":"562363","DOI":"10.3389\/fphar.2020.562363","volume":"11","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zou Y, Pan Z, Zhang H, Deng C, Yuan Y, Guo J, Tang Y, Julie N, Wu W, et al. Efficacy and safety of artemisinin-piperaquine for the treatment of uncomplicated malaria: a systematic review. Front Pharmacol. 2020;11:562363.","journal-title":"Front Pharmacol"},{"key":"2807_CR25","doi-asserted-by":"crossref","unstructured":"Giorgio S, Gallo-Francisco PH, Roque GAS, Fl\u00f3ro E, Silva M. Granulomas in parasitic diseases: the good and the bad. Parasitol Res. 2020;119(10):3165\u201380.","DOI":"10.1007\/s00436-020-06841-x"},{"issue":"5","key":"2807_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10863-020-09843-7","volume":"52","author":"IF Abou-El-Naga","year":"2020","unstructured":"Abou-El-Naga IF. Schistosoma mansoni sarco\/endoplasmic reticulum Ca2\u2009+\u2009ATPases (SERCA): role in reduced sensitivity to praziquantel. J Bioenerg Biomembr. 2020;52(5):397\u2013408.","journal-title":"J Bioenerg Biomembr"},{"issue":"5","key":"2807_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/imcb.12229","volume":"97","author":"E Eyoh","year":"2019","unstructured":"Eyoh E, McCallum P, Killick J, Amanfo S, Mutapi F, Astier AL. The anthelmintic drug praziquantel promotes human Tr1 differentiation. Immunol Cell Biol. 2019;97(5):512\u20138.","journal-title":"Immunol Cell Biol"},{"key":"2807_CR28","doi-asserted-by":"publisher","first-page":"635985","DOI":"10.3389\/fimmu.2021.635985","volume":"12","author":"E Driciru","year":"2021","unstructured":"Driciru E, Koopman JPR, Cose S, Siddiqui AA, Yazdanbakhsh M, Elliott AM, Roestenberg M. Immunological considerations for schistosoma vaccine development: transitioning to endemic settings. Front Immunol. 2021;12:635985.","journal-title":"Front Immunol"},{"issue":"1","key":"2807_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00436-020-06968-x","volume":"120","author":"F Winkelmann","year":"2021","unstructured":"Winkelmann F, Frank M, Rabes A, Koslowski N, Schulz C, Bischofsberger M, Reisinger EC, Sombetzki M. Human serum activates the tegument of female schistosomes and supports recovery from Praziquantel. Parasitol Res. 2021;120(1):209\u201321.","journal-title":"Parasitol Res"},{"key":"2807_CR30","doi-asserted-by":"crossref","unstructured":"Lam NS, Long X, Su X-Z, Lu F. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis. Pharmacol Res. 2018;133:77-100.","DOI":"10.1016\/j.phrs.2018.04.025"},{"key":"2807_CR31","doi-asserted-by":"publisher","first-page":"113193","DOI":"10.1016\/j.ejmech.2021.113193","volume":"213","author":"OPS Patel","year":"2021","unstructured":"Patel OPS, Beteck RM, Legoabe LJ. Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research. Eur J Med Chem. 2021;213:113193.","journal-title":"Eur J Med Chem"},{"key":"2807_CR32","doi-asserted-by":"crossref","unstructured":"Bergquist R, Elmorshedy H. Artemether and praziquantel: origin, mode of action, impact, and suggested application for effective control of human schistosomiasis. Trop Med Infect Dis. 2018;3(4):125.","DOI":"10.3390\/tropicalmed3040125"},{"key":"2807_CR33","doi-asserted-by":"crossref","unstructured":"Couto FFB, Coelho PM, Z, Ara\u00fajo N, Kusel JR, Katz N, Jannotti-Passos LK, Mattos ACA. Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz. 2011;106(2):153\u20137.","DOI":"10.1590\/S0074-02762011000200006"},{"key":"2807_CR34","doi-asserted-by":"crossref","unstructured":"Gouveia MJ, Brindley PJ, G\u00e4rtner F, Costa J, Vale N. Drug repurposing for schistosomiasis: combinations of drugs or biomolecules. Pharmaceuticals (Basel) 2018;11(1).","DOI":"10.3390\/ph11010015"},{"key":"2807_CR35","doi-asserted-by":"publisher","first-page":"1646155","DOI":"10.3389\/fvets.2025.1646155","volume":"12","author":"ES El-Wakil","year":"2025","unstructured":"El-Wakil ES, Tolba MM, El-Sayad MH, Khairy Hassen M, Al-Rashidi HS, Almayouf MA, Al-Megrin WA, I, Alzaylaee H, Moneer EA. A comparative parasitological, histopathological, and proteomic analysis of Schistosoma mansoni infected mice treated with ivermectin and praziquantel. Front Vet Sci. 2025;12:1646155.","journal-title":"Front Vet Sci"},{"issue":"7","key":"2807_CR36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1039\/D0NP00079E","volume":"38","author":"HN Lyu","year":"2021","unstructured":"Lyu HN, Ma N, Meng Y, Zhang X, Wong YK, Xu C, Liao F, Jiang T, Tu Y, Wang J. Study towards improving artemisinin-based combination therapies. Nat Prod Rep. 2021;38(7):1243\u201350.","journal-title":"Nat Prod Rep"}],"updated-by":[{"DOI":"10.1007\/s15010-026-02851-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02807-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02807-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02807-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:10:24Z","timestamp":1786702224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02807-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2807"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02807-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-026-02851-6","URL":"https:\/\/doi.org\/10.1007\/s15010-026-02851-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}